Frequencies of mutation occurrence within targeted gene panel between two subtypes of CBF-AML, irrespective of genes, were comparable (93.5% in t(8;21) AML and 88% in inv(16) AML, p < 0.29). This evidence concerns the gene CEBPZ and acute myeloid leukemia.